Furthermore, the combination of anti-VEGF/VEGFR and PD-1/PD-L1 inhibitors has been granted FDA approval for the treatment of hepatocellular carcinoma and renal cell carcinoma [63–65]. Here, CD274 is linked to renal cell carcinoma.